Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 Inhibitor fit in the management of type 2 diabetes?

Diabetes Care

Volumn 38, Issue 3, 2015, Pages 373-375

  Abdul Ghani, Muhammad ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; SAXAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ADAMANTANE; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIPEPTIDES; GLUCOSIDES; METFORMIN;

ANTIDIABETIC ACTIVITY; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRACTICE GUIDELINE; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; HUMANS; MALE;

ADAMANTANE; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; FEMALE; GLUCOSIDES; HUMANS; MALE; METFORMIN;

EID: 84940101393     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2517     Document Type: Note

References (13)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977- 986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
3. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-86.
4. Eckerle Mize DL, Salehi M. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. Curr Diab Rep 2013;13:307- 318.
5. Abdul-Ghani MA, Norton L, De Fronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-531.
6. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after singledose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92: 1249-1255.
7. De Fronzo RA. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795.
8. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509-514.
9. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508.
10. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition ofsaxagliptin or dapagliflozin to metformin. Diabetes Care 2015;38:376-383.
11. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140- 149.
12. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38:384-393.
13. Abdul-Ghani MA, De Fronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 2013;62:3324-3328.